Evidence map›Paper›PMID 34683977›Full record

ArticlePharmaceutics2021

Development of a 3D-Printed Dosing Platform to Aid in Zolpidem Withdrawal Therapy.

Silke Henry, Lien De Vadder, Milan Decorte, Susanna Francia, Magali Van Steenkiste, Jan Saevels, Valérie Vanhoorne, Chris Vervaet

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. InvestigatingHeliyon · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Silke HenryLaboratory of Pharmaceutical Technology, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0001-6834-5310
Lien De VadderLaboratory of Pharmaceutical Technology, Ghent University, 9000 Ghent, Belgium.
Milan DecorteLaboratory of Pharmaceutical Technology, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-8042-9514
Susanna FranciaLaboratory of Pharmaceutical Technology, Università Di Pavia, 27100 Pavia, Italy.ORCID 0000-0002-5899-9713
Magali Van SteenkisteAlgemene Pharmaceutische Bond, 1000 Brussels, Belgium.
Jan SaevelsAlgemene Pharmaceutische Bond, 1000 Brussels, Belgium.
Valérie VanhoorneLaboratory of Pharmaceutical Technology, Ghent University, 9000 Ghent, Belgium.
Chris VervaetLaboratory of Pharmaceutical Technology, Ghent University, 9000 Ghent, Belgium.
Ghent University · BEUniversity of Pavia · IT

Funding

Flanders Innovation and Entrepreneurship HBC.2020.2203
6 · The paper itself

Abstract

The long-term use of benzodiazepine receptor agonists (BZRAs) is associated with multiple side effects, such as increased sedation, hangover or an elevated risk of dependency and abuse. Unfortunately, the long-term use of BZRAs is reaching worrying intake rates, and therefore, the need for action is high. It was demonstrated already that the overall willingness of patients for deprescription increased when a slow dose reduction scheme with the possibility for dose increase, if needed, is employed. The current study aims to develop a flexible dosing platform of zolpidem hemitartrate (ZHT) to facilitate such withdrawal therapy. As this is the first report on the extrusion and 3D printing of ZHT, its thermal behaviour and sensitivity towards photolytic degradation was characterised. It was shown that ZHT possesses multiple polymorphs and was especially prone to oxidative photolysis. Next, a variety of immediate release polymers (Eudragit EPO, Kollidon VA64, Kollidon 12PF and Soluplus) were blended and extruded with Polyox WSR N10 to investigate their feedability and printability by mechanical and rheological analysis. The addition of PEO was shown to enable printing of these brittle pharmaceutical polymers, although the processing temperature was deemed critical to avoid surface defects on the resulting filaments. An EPO(70)PEO(30) system was selected based on its suitable mechanical properties and low hygroscopicity favoring ZHT stability. The matrix was blended with 1% or 10% API. The effect of certain printing parameters (caplet size, nozzle diameter, % overlap) on dissolution behaviour and caplet weight/dimensions/quality was assessed. A flexible dosing platform capable of delivering <1 mg and up to 10 mg of ZHT was created. Either caplet modification (incorporation of channels) or disintegrant addition (Primojel, Explotab, Ac-Di-Sol, Primellose and Polyplasdone-XL) failed to achieve an immediate release profile. This study provides the first report of a 3D-printed flexible dosing platform containing ZHT to aid in withdrawal therapy.

Indexed as

3D printingextrusionfused deposition modelingpersonalised medicinezolpidem

Identifiers

PMID34683977
PMCPMC8541164
OpenAlexW3205673680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.